April 2009
Emergency Preparedness News;Apr2009, Vol. 33 Issue 4, p5
Trade Publication
The article reports on the new anthrax vaccine under clinical trials and awaits approval from the U.S. Food and Drug Administration. According to its British manufacturer Avecia Biologics Ltd., no safety problems emerged, and the vaccine produced responses that suggested people were developing immunity to anthrax.


Related Articles

  • Nanotech could be key to new anthrax detection test. PEDERSEN, AMANDA // Medical Device Daily;3/23/2009, Vol. 13 Issue 54, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has completed a proof-of-concept study of a test designed to detect the presence of even the smallest amount of the anthrax toxin. Study author Indira Hewlett said the FDA findings could form the basis of a test that allows...

  • Bad bugs need more drugs. Opar, Alisa // Nature Reviews Drug Discovery;Dec2007, Vol. 6 Issue 12, p943 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to issue the first of its long-awaited guidelines for clinical trials of drugs to treat bacterial infections. It states that prompted by the Infectious Diseases Society of America (IDSA), the requirement to issue...

  • FDA Guidance for ABSSSI Trials: Implications for Conducting and Interpreting Clinical Trials. Itani, Kamal M. F.; Shorr, Andrew F. // Clinical Infectious Diseases;Jan2014, Vol. 58 Issue suppl_1, pS4 

    Recent guidance from the US Food and Drug Administration (FDA) on the conduct of clinical trials for acute bacterial skin and skin structure infection (ABSSSI) has changed the framework for clinical trial design and conduct. Notable changes included new disease state definitions, new primary...

  • NO MORE ANTHRAX VACCINATION.  // New Scientist;11/6/2004, Vol. 184 Issue 2472, p6 

    This article presents information on anthrax vaccination. A U.S. federal judge has ruled that the mandatory vaccination of all U.S. military personnel against anthrax must stop. The suit brought by six soldiers claimed the vaccine was never proved effective against inhaled anthrax, the form a...

  • Cattle Call. Orent, Wendy // New Republic;11/12/2001, Vol. 225 Issue 20, p16 

    Presents information on the vulnerability to anthrax poisoning. Information on the fact that there is only enough anthrax vaccine in the U.S. today to inoculate 4,000 people; Failure of the company that makes the vaccine, BioPort Corp., to meet the U.S. Food and Drug Administration regulations;...

  • B-TECH UPDATE. Thomas III, Calhoun "Reb" // SciTech Lawyer;Fall2008, Vol. 5 Issue 2, p32 

    The article presents an update on the biotechnology industry in the U.S. The anthrax case tragedy in 2001 led to the analysis of anthrax bacteria spores in 2008. The House of Democrats showed a unanimous support in giving the regulatory control of tobacco products to the Food and Drug...

  • News. Kaye, Donald // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, piii 

    This article presents news brief related to several recent developments related to medical care. It is informed that a diagnostic test has been developed by Immunetics Inc. to diagnose the anthrax causing bacteria. It is informed that the test has been approved by the U.S. Food and Drug...

  • US Food and Drug Administration Approval of Ciprofloxacin Hydrochloride for Management of Postexposure Inhalational Anthrax. Meyerhoff, Andrea; Albrecht, Renata; Meyer, Joette M.; Dionne, Peter; Higgins, Karen; Murphy, Dianne // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p303 

    In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax. This was the first antimicrobial drug approved by the FDA for use in treating an infection due to a biological agent used...

  • Smallpox vaccine development quickened. Birmingham, Karen; Kenyon, Georgina // Nature Medicine;Nov2001, Vol. 7 Issue 11, p1167 

    Reports on the approval of the U.S. Food and Drug Administration for the treatment of inhalation anthrax. Increase of the number of gastrointestinal anthrax; Accounts on the risk factor for the development of cutaneous anthrax; Emphasis on the events considered as an act of bioterrorism;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics